BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7493354)

  • 21. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    O'Donnell RT; Shen S; Denardo SJ; Wun T; Kukis DL; Goldstein DS; Denardo GL
    Anticancer Res; 2000; 20(5C):3647-55. PubMed ID: 11268433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
    Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
    Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
    Acta Oncol; 2005; 44(6):579-88. PubMed ID: 16165917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
    Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
    Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy.
    Wilder RB; DeNardo GL; Sheri S; Fowler JF; Wessels BW; DeNardo SJ
    Eur J Nucl Med; 1996 Aug; 23(8):953-7. PubMed ID: 8753685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
    DeNardo SJ; DeNardo GL; Kukis DL; Shen S; Kroger LA; DeNardo DA; Goldstein DS; Mirick GR; Salako Q; Mausner LF; Srivastava SC; Meares CF
    J Nucl Med; 1999 Feb; 40(2):302-10. PubMed ID: 10025839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
    Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
    J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
    Czuczman MS; Straus DJ; Divgi CR; Graham M; Garin-Chesa P; Finn R; Myers J; Old LJ; Larson SM; Scheinberg DA
    J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
    Boucek JA; Turner JH
    Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
    Koral KF; Dewaraja Y; Li J; Lin Q; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    J Nucl Med; 2003 Mar; 44(3):457-64. PubMed ID: 12621015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.
    DeNardo DA; DeNardo GL; Yuan A; Shen S; DeNardo SJ; Macey DJ; Lamborn KR; Mahe M; Groch MW; Erwin WD
    J Nucl Med; 1996 Dec; 37(12):1970-5. PubMed ID: 8970516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging and treatment of B-cell lymphoma.
    Eary JF; Press OW; Badger CC; Durack LD; Richter KY; Addison SJ; Krohn KA; Fisher DR; Porter BA; Williams DL
    J Nucl Med; 1990 Aug; 31(8):1257-68. PubMed ID: 2384792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
    Schillaci O; DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; O'Donnell RT; Lamborn KR
    Cancer Biother Radiopharm; 2007 Aug; 22(4):521-30. PubMed ID: 17803447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
    Ferrer L; Kraeber-Bodéré F; Bodet-Milin C; Rousseau C; Le Gouill S; Wegener WA; Goldenberg DM; Bardiès M
    Cancer; 2010 Feb; 116(4 Suppl):1093-100. PubMed ID: 20127958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
    Wahl RL; Zasadny KR; MacFarlane D; Francis IR; Ross CW; Estes J; Fisher S; Regan D; Kroll S; Kaminski MS
    J Nucl Med; 1998 Aug; 39(8 Suppl):21S-27S. PubMed ID: 9708567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of myelotoxicity using semi-quantitative marrow image scores.
    Lim S; DeNardo GL; DeNardo DA; O'Donnell RT; Yuan A; DeNardo SJ
    J Nucl Med; 1997 Nov; 38(11):1749-53. PubMed ID: 9374345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
    DeNardo GL; Kukis DL; Shen S; DeNardo DA; Meares CF; DeNardo SJ
    Clin Cancer Res; 1999 Mar; 5(3):533-41. PubMed ID: 10100704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
    Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
    J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
    Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
    N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.